Krystal Biotech, Inc. Common Stock vs. Kymera Therapeutics, Inc. Common Stock
KRYS
Krystal Biotech, Inc. Common Stock
$337.02 -1.84%
VS KYMRKymera Therapeutics, Inc. Common Stock
$121.50 -4.56%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| KRYS | KYMR | |
|---|---|---|
| Market Cap | $10.16 billion | $10.59 billion |
| Revenue (TTM) | $440.48 million | $105.00 million |
| Net Income (TTM) | $241.47 million | $-299,601,000 |
KRYS leads on 2 of 3 size & scale factors.
Valuation
| KRYS | KYMR | |
|---|---|---|
| P/E Ratio | 42.23 | — |
| Price / Book | 7.48 | 7.01 |
| Price / Sales | 23.07 | 100.82 |
KRYS and KYMR split the valuation factors evenly.
Profitability
| KRYS | KYMR | |
|---|---|---|
| Net Margin | 54.82% | -285.34% |
| Return on Equity | 17.77% | -19.85% |
KRYS leads on 2 of 2 profitability factors.
Risk & Sentiment
| KRYS | KYMR | |
|---|---|---|
| Short Interest | 0.11% | 0.24% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.